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Purpose: Cone beam computed tomography (CBCT) is fast becoming standard on modern linear
accelerators. CBCT increases the dose to regions within and outside the treatment field, potentially
increasing secondary cancer induction and toxicity. This study quantified megavoltage (MV) CBCT
skin dose and compared it to skin dose delivered during standard tangential breast radiotherapy.
Method: Dosimetry was performed both in- and out-of-field using thermoluminescent dosimeters
(TLDs) and a metal-oxide-semiconductor-field-effect-transistor (MOSFET) detector specifically
designed for skin dosimetry; these were placed superficially on a female anthropomorphic phantom.
Results: The skin dose from a single treatment fraction ranged from 0.5 to 1.4 Gy on the ipsilateral
breast, 0.031–0.18 Gy on the contralateral breast, and 0–0.02 Gy in the head and pelvic region. An 8
MU MV CBCT delivered a skin dose that ranged from 0.02 to 0.05 Gy in the chest region and was less
than 0.01 Gy in the head and pelvis regions. One MV CBCT per fraction was found to increase the out-
of-field skin dose from both the CBCT and the treatment fields by approximately 20%. The imaging
dose as a percentage of treatment doses in the ipsilateral breast region was 3% for both dosimeters.
Conclusion: Imaging increases the skin dose to regions outside the treatment field particularly
regions immediately adjacent the target volume. This small extra dose to the breasts should be con-
sidered when developing clinical protocols and assessing dose for clinical trials. VC 2011 American
Association of Physicists in Medicine. [DOI: 10.1118/1.3641867]
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I. INTRODUCTION
Image-guided radiotherapy (IGRT) utilizes advanced imag-
ing technology in the treatment room to ensure correct
patient setup. Megavoltage (MV) cone beam computed to-
mography (CBCT) (Ref. 1) is a technology used for IGRT
that employs the medical linear accelerator treatment beam
and an amorphous silicon flat panel detector to acquire pro-
jections of the patient. Cone beam reconstruction technology
is then used to reconstruct a volumetric image of the patient.
In an era of increasing use of IGRT technologies where
multiple images are taken during the treatment course, extra
radiation dose to the patient from imaging should be consid-
ered. In particular, repeated imaging could potentially exacer-
bate radiation-induced skin toxicity by increasing the in-field
skin dose. To the best of our knowledge, there have been no
studies evaluating the influence of concomitant imaging on
skin toxicity. In breast radiotherapy, total treatment doses of
greater than 50 Gy and larger fraction sizes have been associ-
ated with greater skin toxicities.2–4 If imaging were to increase
the fraction dose or total treatment dose, to 60 Gy for example,
the patient may experience worse skin reactions. Radiation-
induced skin toxicity is a side effect most breast cancer radio-
therapy patients (74%–100%) will experience during their
treatment.5–8 The dose to the skin can vary considerably inside
and outside the treatment field. Knowledge of this dose is
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important in order to identify areas where unwanted skin reac-
tions may occur. The imaging dose may also contribute to a
delivered dose that exceeds the prescribed dose.
Skin dose can vary considerably due to its dependence upon
a number of factors such as treatment field dimensions, the use
of beam modifying devices, and the obliquity of the beam.
Additionally, skin thickness varies considerably over the entire
body; breast skin thickness ranges from 0.6 to 2.7 mm.9,10 Con-
sequently, skin dose is difficult to assess and measure, particu-
larly in vivo. In vivo skin dose measurements can be acquired
by measuring the dose at various depths and extrapolating to
the desired depth. This technique can be completed with multi-
ple thermoluminescent dosimeters (TLDs) of different thick-
ness11 or multilayer Gafchromic film.12 However, both
methods can be time consuming due to multiple calibrations
and both methods only provide retrospective dose information.
Another option for in vivo skin dosimetry is to use a dosimeter
with a small measurement depth (less than 1 mm) such as
carbon-loaded TLDs,13 radiochromic film,14 or metal-oxide-
semiconductor-field-effect-transistor (MOSFETs).15 In the clin-
ical environment, the most commonly used detectors for
in vivo dosimetry are diodes and TLDs.16
The skin dose to various regions such as the contralateral
breast from different breast radiotherapy techniques has been
well reported.17–19 Kilovoltage (kV) CBCT is the most com-
mon imaging modality provided by several vendors (XVIVR ,
Elekta Oncology Systems; OBI, Varian Medical Systems; Ar-
tiste, Siemens); however, MV CBCT (Ref. 1) still makes up a
substantial proportion of the imaging systems integrated with
linear accelerators. In the literature, there is limited in vivo
skin dose values available for MV CBCT, the image modality
investigated in this study. A Monte Carlo study20 provides a
single value for the whole body skin dose from a head and
neck MV CBCT (0.59 cGy for an 8 MU MV CBCT) and a
pelvis MV CBCT (0.94 cGy for an 8 MU MV CBCT). In this
study,20 no region specific skin dose values were provided,
such as the dose delivered in or out of the imaging field-of-
view, and hence skin dose assessment to areas deemed at high
risk of radiation skin damage, such as the eyes in head and
neck radiotherapy, was not possible.
This report details a phantom study conducted for the pur-
pose of investigating the additional skin dose a MV CBCT
delivers to a female patient during a standard tangential
breast radiotherapy fraction. Dosimetry was performed both
in- and out-of-field using TLDs and a MOSFET detector spe-
cifically designed for skin dosimetry, the MOSkin MOSFET.
II. MATERIALS AND METHODS
II.A. Phantom, treatment plan, and megavoltage cone
beam CT
A female anthropomorphic phantom (Radiology Support
Devices, USA) was utilized for this study. Twenty-two point
positions on the phantoms surface in the head and neck, chest,
and pelvic region were chosen to measure the radiation skin
dose from the breast radiotherapy treatment and MV CBCT
image protocol described below. The measurement locations
are shown in Fig. 1. The skin dose was measured with TLDs
and MOSFETs, with specifications described in Secs. II B and
II C, respectively.
A standard breast radiotherapy treatment plan was devel-
oped for the left breast according to departmental protocol.
The plan consisted of opposed tangential breast fields, at
gantry angles 309 and 134, with 15 virtual wedges, and a
standard dose regimen of 50 Gy (designed to be delivered in
2 Gy fractions). Five fractions were delivered to the phantom
in a single measurement, this ensured detectors at out-
of-field treatment positions received a significant signal
beyond the noise background threshold. Measured skin dose
values were then extrapolated back to a single fraction dose.
A 60 MU MV CBCT imaging protocol was applied to the
phantom. This high imaging dose assisted dosimetric
response signal for both detectors and rendered background
noise minimal. The image acquisition parameters included
6 MV photons, 200 rotation arc, 27.4 27.4 cm field-
of-view, 256 256 reconstruction matrix, and 0.1 cm slice
thickness. Measured dose values were scaled to Gy=MU and
from this the dose for an 8 MU protocol was determined.
The contralateral breast, points C1–C6, and ipsilateral breast,
points C7–C12, are within the MV CBCT field-of-view.
A daily imaging schedule was investigated in this study,
as this would deliver the highest skin dose to the patient and
FIG. 1. Three-dimensional CT-render of female anthropomorphic phantom,
illustrating the approximate radiation detector locations.
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thus a “worst case” scenario is presented. It is recognized
that clinically for breast radiotherapy a weekly image sched-
ule would be most likely.21,22
The breast treatment and MV CBCT protocol described
above was delivered to the phantom using a Siemens Oncor
linear accelerator (Siemens Medical Solutions, Erlangen,
Germany) operating at 6 MV. Dose measurements were
repeated twice to obtain statistical variation.
II.B. Thermoluminescent dosimetry
Standard 3 3 0.9 mm lithium-fluoride TLD-100 chips
(Harshaw, Erlangen, Germany) with a measurement water
equivalent depth (WED) of approximately 1 mm (Ref. 23)
were used. TLD chips were irradiated to known doses within
the expected range of MV CBCT and breast radiotherapy
energies (6 MV) and doses (0.1, 0.2, 0.5, 1, and 2 Gy) to es-
tablish TLD sensitivity and individual chip calibration fac-
tors. Only TLD chips with sensitivity ranging within 65%
were selected for measurements in this study. TLD chips
were read within 24 h of irradiation with a Rialto NE TLD
reader (NE Technology Ltd, UK). Two TLD chips were
placed at each location to reduce statistical error in the dose
measurements.
II.C. MOSFET dosimetry
The MOSFET detector utilized for this study was the
MOSkin, a MOSFET designed specifically for skin dosime-
try.24 The MOSkin MOSFET has a uniform build-up layer
with a measurement WED of 0.07 mm,24 the International
Commission on Radiological Protection (ICRP) defines
this depth as radiosensitive basal layer of the skin.25 The
total detector size including packaging is 2 5 0.7 mm.
The MOSFETs surface dose response increases with
increasing beam obliquity.19 Previous studies have utilized
this MOSFET for in-field skin and surface dosimetry.19,26 Also
for rectal wall interface dosimetry27 and for brachytherapy
applications.24
The accuracy of the MOSFET, utilized for this study, for
out-of-field dosimetry was assessed. The MOSFET response
for a 10 10 cm, 6 MV beam was measured at 2 and 15 mm
depth (dmax) in solid water, at the following distances from
the central axis 0, 6, 8, 10, 15, 20, and 25 cm. The 2 mm
depth measurements were compared with an Attix ionization
chamber (at 2 mm depth) in the exact same setup for com-
parison. The Attix chamber has a large guard ring and is
optimized for build-up measurements.28 The MOSFET dose
measurements were then compared with a thimble chamber
(at 15 mm depth) as the thimble chamber is not optimized
for measurements in the build-up region.
MOSFET surface doses at each measurement location
were obtained by multiplying the difference of the threshold
voltage before and after irradiation by a calibration factor.
The calibration factor was determined by irradiating the
MOSFETs to a known dose in standard conditions in a
6 MV beam, before and after measurements. The average
calibration factor was utilized for treatment and imaging
measurements.
III. RESULTS
The out-of-field MOSFET response is illustrated in Fig. 2
for a 6 MV beam 10 10 cm field at distances 0, 6, 8, 10,
15, 20, and 25 cm from the central axis, and at depths 2 and
15 mm. Agreement within 0.1% was observed between the
MOSFET and ionization chamber measurements, with the
exception at depth 2 mm, 6 cm from the central axis, where
2% agreement was observed. Discrepancy between the Attix
ionization chamber and the MOSFETs at a distance 6 cm
from the central axis is attributable to the larger surface area
of the chamber resulting in a section of the attix chamber
sensitive volume residing in the radiation field.
The skin dose measured for a single treatment fraction
and an 8 MU MV CBCT scan in the head, contralateral
breast, ipsilateral breast and pelvic region is outlined in
Table I. The skin dose from a single 8 MU MV CBCT was
less than 0.01 Gy in the head and pelvis regions and ranged
from 0.02 to 0.05 Gy in the chest region. The skin dose from
a single treatment fraction was less than 0.02 Gy in the head
and pelvic region and ranged from 0.5 to 1.4 Gy on the ipsi-
lateral breast and 0.031–0.18 Gy on the contralateral breast.
Utilizing the measured values from Table I, the single 8
MU MV CBCT image skin dose is presented as a percentage
of a single treatment fraction skin dose in Fig. 3. The imag-
ing dose as a percentage of treatment dose is highest for the
most lateral point of the contralateral breast.
IV. DISCUSSION
Skin dose measurements at a range of locations both in
and out of a tangential breast treatment area for MV CBCT
and treatment delivery have been presented. The MOSkin
MOSFET was shown to be accurate for out-of-field dosime-
try, with the MOSFET and ionization chamber measured
out-of-field doses in agreement to within 0.1% (with the
exception of one point) of the maximal dose in the beam.
This agreed with a similar study29 investigating the MOS-
FET peripheral dose accuracy. At 15 mm depth, 200 mm
FIG. 2. MOSFET response measured out-of-field for a 6 MV 10 10 cm
photon field. The error bars represent the 95% confidence interval of the
mean of three measurements.
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from the central axis, 4000 MU was delivered to the centre
of the 10 10 cm field to ensure the MOSFETs received an
adequate dose whereas 100 MU was delivered for the thim-
ble chamber. However, the dose delivered to the MOSFETs
out-of-field was significantly increased in comparison to the
ionization chambers, to ensure sufficient signal to noise ra-
tio. While using extra MU was practical in this phantom
study, using MOSFETs with a higher sensitivity would be
advantageous for patient dosimetry. The current study used
the MOSkin MOSFETs at þ12 V bias giving a sensitivity of
2.5 mV cGy1, there is potential to significantly increase the
sensitivity by increasing the gate oxide thickness30,31 and
gate bias.32
The present study utilized two detectors to measure skin
dose, both detectors illustrated that MV CBCT verification
imaging increases the skin dose to areas that would not
receive a significant skin dose from treatment alone. If MV
CBCT was utilized for daily image verification during a
standard tangential breast radiotherapy treatment fraction the
skin dose at the lateral side of the contralateral breast would
approximately double. This is attributable to the contralateral
breast being within the MV CBCT field-of-view, as the MV
CBCT acquires projection images in a 200 arc around the
patient to reconstruct the 3D image. Reduced dose may be
acquired by reducing the arc of imaging, however, image
quality would be reduced due to the reduced projection angle.
The skin dose from an 8 MU MV CBCT ranged from
0.03 to 0.05 Gy and 0.02 to 0.03 Gy in the chest region for
the TLDs and MOSFETs, respectively. In comparison,
within the imaging field of a kV CBCT acquired for breast
radiotherapy setup a previous study found the breast skin
dose, measured with the same type of TLDs, received a
lower dose of 0.01 Gy.33 Limited organ and tissue dose
measurements from a chest MV CBCT have been investi-
gated previously with treatment planning systems.34,35 These
studies did not provide skin dose values; thus, a comparison
with the present data could not be made.
The skin dose from a single 2 Gy treatment fraction
ranged from 0.5 to 1.4 Gy on the ipsilateral breast,
0.031–0.18 Gy on the contralateral breast, and 0–0.02 Gy in
the head and pelvic region. The contralateral breast skin
dose values are in agreement with a similar study which
reported doses of 0.022–0.13 Gy.18 The higher doses meas-
ured in the present study are attributable to the phantom
breasts utilized in this study not settling laterally as patients
breasts tend to do. For this reason, the phantoms contralat-
eral breast remains closer to the beam edge and hence may
receive a higher dose.
The MOSFET uncertainty was large at positions outside
the CBCT field-of-view and out-of-field of the treatment
beams, see Table I. This is attributable to the MOSFETs lower
detection limit of approximately 0.15 cGy.36 For this reason,
the MOSFETs utilized in this study would not be suitable for
clinical skin dose measurements far from the treatment or
imaging field-of-views unless, as mentioned above, the gate
oxide thickness30,31 and gate bias32 is increased.
To the best of our knowledge, there have been no studies
evaluating the influence of concomitant imaging on skin
TABLE I. Skin dose measured with TLDs and MOSkins from a single treatment fraction and a single 8 MU MV CBCT to the head and neck region (H1–H6),
the contralateral breast (lateral C1–medial C6), the ipsilateral breast (medial C7–lateral C12), and the pelvic region (P1–P5). The detector positions are
detailed in Fig. 1.
Single treatment fraction Single 8 MU MV CBCT
TLD MOSFET TLD MOSFET
Position Dose (cGy) 695% CI Dose (cGy) 695% CI Dose (cGy) 695% CI Dose (cGy) 695% CI
H1 0.69 6 0.01 0.57 6 0.34 0.09 6 0.05 0.02 6 0.23
H2 1.37 6 0.11 1.67 6 0.13 0.20 6 0.02 0.25 6 0.29
H3 1.79 6 0.12 2.36 6 0.56 0.24 6 0.08 0.16 6 0.20
H4 1.82 6 0.11 1.94 6 0.41 0.22 6 0.01 0.19 6 0.53
H5 0.89 6 0.03 0.94 6 0.45 0.20 6 0.04 0.21 6 0.14
C1 3.10 6 0.11 3.47 6 0.67 3.68 6 0.39 2.19 6 0.27
C2 4.19 6 0.13 4.43 6 0.42 3.57 6 0.45 2.10 6 0.35
C3 7.40 6 0.22 7.82 6 0.51 2.97 6 0.13 1.90 6 0.17
C4 12.7 6 0.09 12.8 6 0.59 3.36 6 0.45 2.08 6 0.22
C5 17.9 6 0.48 18.0 6 0.63 3.80 6 0.52 2.43 6 0.24
C6 24.2 6 2.69 26.7 6 1.37 4.29 6 0.73 2.77 6 0.22
C7 57.8 6 3.22 48.8 6 1.43 4.47 6 0.17 2.99 6 0.26
C8 132 6 2.32 88.1 6 3.30 3.25 6 0.27 2.16 6 0.25
C9 130 6 5.25 99.5 6 3.25 2.90 6 0.06 1.84 6 0.08
C10 151 6 1.27 120 6 1.44 2.71 6 0.31 1.83 6 0.09
C11 128 6 4.21 103 6 2.64 3.17 6 0.19 2.25 6 0.23
C12 135 6 2.86 96.8 6 2.66 3.91 6 0.37 2.74 6 0.14
P1 2.25 6 0.01 2.63 6 0.26 0.62 6 0.07 0.66 6 0.26
P2 0.60 6 0.04 1.10 6 0.09 0.22 6 0.10 0.20 6 0.85
P3 1.13 6 0.01 1.24 6 0.32 0.28 6 0.10 0.29 6 0.50
P4 1.37 6 0.25 1.31 6 0.15 0.23 6 0.01 0.24 6 0.51
P5 0.51 6 0.00 0.36 6 0.23 0.12 6 0.07 0.20 6 0.86
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toxicity. The impact of the MV CBCT imaging dose on skin
toxicity was assessed according to studies which have inves-
tigated the deterministic and stochastic effects of skin irradi-
ation.2,37 This is not ideal, however, was deemed reasonable.
Daily imaging was considered in this study, as this imaging
schedule would deliver the highest imaging dose to the
patient. This schedule would most likely not increase the
possibility of contralateral breast skin reactions as it would
not raise the total contralateral breast skin dose above the
single fraction dose threshold (5 Gy) or total fractionated
dose threshold (approximately 20 Gy) for mild deterministic
effects.2 However, the dose delivered to the contralateral
breast during radiotherapy treatment is associated with an
increased long-term risk of contralateral breast cancer,38 the
additional imaging dose may increase this risk. In the ipsilat-
eral breast region (points C7–C12) the imaging dose as a
percentage of treatment dose was as expected minimal (up to
3%), see Fig. 3. This is attributable to these measurement
points being within both the treatment and CBCT field-of-
view and the imaging dose being small in comparison to the
treatment dose, see Table I. The imaging dose to the head
and pelvic regions was up to 20% of the out-of-field skin
dose delivered from the treatment at the same locations.
The contralateral breast (points C1–C6), head (points
H1–H5) and pelvis (P1–P5) skin dose from the treatment
alone consists of leakage, extra focal scatter and electron
contamination. The contralateral breast is in the MV CBCT
field-of-view and out-of-field of the treatment beams. Hence,
the magnitude of the MV CBCT dose contribution to the
total contralateral breast dose is significantly higher than that
of the breast radiotherapy treatment. The delivered dose
from an 8 MU MV CBCT is up to 118 and 62% of the dose
delivered from treatment, for the TLDs and MOSFETs,
respectively. An 8 MU MV CBCT increases the dose deliv-
ered to location C1 from 0.03 6 0.01 Gy, for both detectors,
for a single treatment fraction to 0.07 6 0.02 Gy and
0.05 6 0.02 Gy, for TLDs and MOSFETs, respectively. The
large percentage difference between the TLD and MOSFETs
is attributable to the detectors measuring similar skin dose
values out-of-field of the treatment beams (at point C1 a dif-
ference of 0.5 cGy) and different skin dose values in the
field-of-view of the CBCT scan (at point C1, a difference of
1.5 cGy). The dose discrepancy in-field of both the MV
CBCT and treatment beams is attributable to differences in
effective depth dose measurements. The MOSkin MOSFET
WED of measurement is 0.07 mm whereas for the TLDs the
WED is approximately 1 mm. Large charged-particle dise-
quilibrium exists at these depths and thus a small change in
depth will result in a large change in dose measured. Out-of-
field the photon spectrum does not vary significantly39,40 and
hence the measurement WED of the detector has little effect
on the dose measurement. Consequently, the TLD and MOS-
FET skin dose measurements in the head and pelvic region
were within one standard deviation of each other.
Measurements in this study were completed under ideal
conditions in that the phantom utilized was moderately
inflexible and hence could be set up consistently. The sin-
gle size and shape of the female anthropomorphic phantom
limited the study as the interpatient variation seen in prac-
tice is not represented by these measurements. Additionally,
the phantoms breasts sit upright on the chest wall and do
not fall laterally with gravity, as a patient’s breast might.
Consequently, the phantoms contralateral breast remains
closer to the edge of the treatment beam and hence may
result in a higher measured dose in comparison to a typical
patient.
Knowledge of the imaging skin dose separate from that of
the treatment dose is necessary in order to assess its impact
on side effects such as skin toxicity. This can be accom-
plished with the TLDs and MOSFETs utilized in this study.
The MOSFETs allow real time skin dose measurements and
hence may be more practical for future in-field in vivo
measurements.
V. CONCLUSION
One MV CBCT per fraction was found to increase the
out-of-field skin dose by approximately 20%. The contralat-
eral breast skin dose from the treatment alone consists of
leakage, extra focal scatter and electron contamination. The
magnitude of the MV CBCT dose contribution is signifi-
cantly higher than this. It is up to 118 and 62% of the dose
delivered from treatment, for the TLDs and MOSFETs,
respectively. In comparison, the imaging dose as a percent-
age of treatment doses in the ipsilateral breast region was
3% for both dosimeters. This extra dose will most likely not
increase the skin toxicity in the treated breast. The skin dose
to the contralateral breast is probably not enough to induce
skin reactions but will add to the risk of second malig-
nancy.38 With the advent of new interface dosimeters accu-
rate in vivo skin dose assessment is possible, linking this
dose assessment to patient’s reactions and secondary cancer
risk remains the next challenge.
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FIG. 3. The measured skin dose from a single 8 MU MV CBCT is presented
as a percentage of the measured skin dose from a single treatment fraction.
The error bars represent 95% confidence intervals.
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